Clinical Trial Detail

NCT ID NCT03663166
Title Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute

lung non-small cell carcinoma


Cisplatin + Ipilimumab + Pemetrexed Disodium


Carboplatin + Ipilimumab + Paclitaxel

Cisplatin + Etoposide + Ipilimumab

Age Groups: adult senior

No variant requirements are available.